预约演示
更新于：2026-05-09
Polidocanol
聚多卡醇
更新于：2026-05-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1991-06-28), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H30O2 |
InChIKeySFNALCNOMXIBKG-UHFFFAOYSA-N |
CAS号9002-92-0 |
关联
71
项与 聚多卡醇 相关的临床试验NCT07561320
Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein: Randomized Clinical Trial
NCT07276243
Comparação da eficácia clínica e estética Entre o Tratamento de Varizes Com Espuma de Polidocanol Associada ou não ao Laser transdérmico: Ensaio clínico Randomizado
RBR-6v2mz6f
Clinical and Aesthetic Efficacy of Polidocanol Foam Sclerotherapy Associated or Not With Transdermal Nd:YAG Laser in Lower Limb Varicose Veins: A Randomized Controlled Trial - FOAM-LASER Foam Sclerotherapy With or Without Transdermal Laser for Varicose Veins
100 项与 聚多卡醇 相关的临床结果
登录后查看更多信息
100 项与 聚多卡醇 相关的转化医学
登录后查看更多信息
100 项与 聚多卡醇 相关的专利（医药）
登录后查看更多信息
1,244
项与 聚多卡醇 相关的文献（医药）2026-12-31INTERNATIONAL JOURNAL OF HYPERTHERMIA
Polidocanol augments high-intensity focused ultrasound efficacy for hyperintense fibroids on T2WI: a retrospective cohort study
Review
作者: He, Hong-ni ; Tang, Ying ; He, Tian-wen ; Tian, Ling ; Lin, Chuan ; Hu, Hui-quan ; Yang, Ming-tao ; Xia, Yu ; Li, Jun
OBJECTIVE:
To compare the immediate efficacy and safety of high-intensity focused ultrasound (HIFU) monotherapy with the combination of ultrasound-guided intratumoral polidocanol injection and HIFU for the treatment of uterine fibroids with high T2-weighted imaging (T2WI) signal intensity.
METHODS:
In this retrospective study, 116 patients with T2-hyperintense uterine fibroids treated between January 2024 and May 2025 were enrolled. Patients were allocated to either HIFU monotherapy (the H group, n = 63) or combined polidocanol and HIFU therapy (the H + P group, n = 53). Thereafter, therapeutic parameters, the non-perfused volume ratio (NPVR), and adverse events were compared between the two groups after propensity score matching.
RESULTS:
The matched cohort comprised 53 patients per group. The median NPVR was significantly higher in the H + P group than in the H group (92.57% vs. 77.81%, p < 0.001). Additionally, a significantly greater proportion of patients in the H + P group achieved an NPVR ≥ 80% (87% vs. 43%, p < 0.001) and an NPVR ≥ 90% (60% vs. 9%, p < 0.001). The H + P group also required significantly less sonication time and lower total energy delivery (both p < 0.05). Furthermore, the overall incidence of adverse events was similar between the two groups (73.6% vs. 69.8%, p = 0.506). However, the H + P group exhibited a markedly lower incidence of sacrococcygeal pain (5.7% vs. 45.3%, p < 0.001).
CONCLUSION:
Pretreatment with ultrasound-guided intratumoral polidocanol injection may improve the immediate ablation efficacy of HIFU in T2-hyperintense uterine fibroids, reducing energy requirements and mitigating procedure-related sacrococcygeal pain. These findings highlight the potential of this combined therapy and underscore the need for prospective studies to confirm its long-term clinical benefits.
2026-12-31Journal of Maternal-Fetal & Neonatal Medicine
Lauromacrogol pericystic injection combined with curettage vs. uterine artery embolization with curettage for cesarean scar pregnancy
Article
作者: Sun, Guoquan ; Ying, Lijie ; Liu, Ling ; Sun, Yaqing
OBJECTIVE:
With the policy of allowing all couples to have three children unveiled in China, the cesarean section rate has increased, leading to a corresponding rise in the number of cesarean scar pregnancy (CSP) cases. Therefore, improving the treatment quality is very important. This article is to compare the efficacy of two different methods treating CSP: Lauromacrogol pericystic injection combined with curettage and uterine artery embolization with curettage.
METHODS:
We performed a retrospective study at Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine (Hangzhou, China) of 55 patients diagnosed with CSP between January 2016 and December 2021. Patients were consecutively assigned to treatment groups: the lauromacrogol treatment group (n = 23) and the uterine artery embolization treatment group (n = 22). The amount of bleeding during and after uterine curettage, the recovery time of human chorionic gonadotropin (β-HCG), hospitalization time, hospitalization expenses, menstrual recovery time, ovulation recovery time, postoperative ovarian function, postoperative pain scores, and adverse reactions were compared between the two groups.
RESULTS:
All patients were successfully treated without major intraoperative complications. The amount of bleeding during and after uterine curettage, the recovery time of β-HCG, and menstrual recovery time showed no significant differences between the two groups (p > 0.05). However, the lauromacrogol group demonstrated significantly shorter ovulation recovery time (96.45 ± 11.64 days vs. 113.76 ± 14.33 days, p < 0.001) and better postoperative ovarian function profiles with lower FSH and LH levels and higher E2 and AMH levels (all p < 0.05). The hospitalization cost in the lauromacrogol group was significantly lower than that in the uterine artery embolization group (¥6863.27 ± 908.22 vs. ¥20747.02 ± 4963.43, p < 0.001), and the incidence of adverse reactions was significantly less than that in the uterine artery embolization group (17.39% vs. 45.45%, p < 0.05). Postoperative pain scores at 2 and 4 weeks were also significantly lower in the lauromacrogol group (p < 0.05).
CONCLUSION:
Lauromacrogol injection around the pregnancy sac combined with curettage and uterine artery embolization combined with curettage demonstrated comparable efficacy in terms of bleeding control, β-HCG recovery, and menstrual resumption for the treatment of cesarean scar pregnancy. However, the lauromacrogol approach offered significant advantages including lower cost, better preservation of ovarian function, faster ovulation recovery, reduced postoperative pain, and fewer adverse reactions, making it suitable for broader adoption in hospitals, particularly those without interventional radiology facilities.
2026-07-01Journal of Vascular Surgery-Venous and Lymphatic Disorders
Comparison of polidocanol endovenous microfoam (Varithena) to physician-compounded foam in sclerotherapy treatment of truncal varicosities: A systematic review and network meta-analysis
Review
作者: Turner, Benedict ; Davies, Alun H ; Chen, Runzhi ; Soh, Chien Lin ; Salih, Marwah ; Tan, Matthew ; Onida, Sarah
BACKGROUND:
Commercial premixed foam sclerosants such as Varithena, a polidocanol endovenous microfoam, have been developed and marketed as better alternatives to physician-compounded foams (PCFs). The aim of this study was to evaluate the efficacy of Varithena compared with PCFs in foam sclerotherapy for the treatment of truncal varicose veins.
METHODS:
A systematic review was performed according to PRISMA and Meta-Analysis guidelines with a registered protocol (PROSPERO: CRD42024494805) using Medline and EMBASE databases from inception to June 17, 2025, by two reviewers. Randomized controlled trials that reported on occlusion rates after truncal varicose vein treatment with foam sclerotherapy were included. A network meta-analysis was performed.
RESULTS:
Six randomized controlled trials with a total of 1726 patients were identified. Complete occlusion was defined as elimination of saphenofemoral junction reflux or occlusion of the saphenous vein on duplex imaging. The median follow-up was 39 weeks (range, 12-52 weeks). No significant difference was observed between Varithena and PCF with respect to occlusion rates at follow-up (risk ratio [RR], 1.12; 95% confidence interval [CI], 0.93-1.35; I2 =71%). Moreover, similar rates of adverse events were observed between the Varithena and PCF groups (RR, 2.89; 95% CI, 0.64-12.97; I2 = 0%). Compared with foam sclerotherapy with Varithena, surgical removal and endovenous laser ablation showed a significantly higher occlusion rate at follow-up (RR, 1.31; 95% CI, 1.18-1.47; I2 =71% and RR, 1.32; 95% CI, 1.18-1.49; I2 =71%, respectively).
CONCLUSIONS:
In patients with saphenous varices, there was no indication that Varithena was superior to or associated with fewer complications than PCFs Further trials are required to define the role of Varithena in the treatment of varicose veins, especially within the context of less expensive alternatives.
100 项与 聚多卡醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原静脉曲张 | 日本 | 2006-07-26 | |
| 静脉曲张 | 澳大利亚 | 2001-07-27 | |
| 食道静脉出血 | 日本 | 1991-06-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 静脉功能不全 | 临床3期 | 美国 | 2010-09-01 | |
| 毛细血管扩张 | 临床3期 | 德国 | 2006-11-08 | |
| 静脉血管疾病 | 临床3期 | 德国 | 2006-11-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 43 | (Varithena®) | 糧夢構廠齋蓋築築窪網(齋選築築齋廠鏇衊繭鹽) = 鬱夢築繭廠鹽選襯鏇蓋 糧製鏇糧餘觸憲艱淵蓋 (鏇觸鏇齋糧蓋網繭繭製, 8.23) 更多 | - | 2026-03-20 | ||
FDA-approved Endothermal Ablation (ETA) systems (FDA-approved ETA Systems) | 糧夢構廠齋蓋築築窪網(齋選築築齋廠鏇衊繭鹽) = 醖鹹網餘膚繭鹹願蓋積 糧製鏇糧餘觸憲艱淵蓋 (鏇觸鏇齋糧蓋網繭繭製, 4.55) 更多 | ||||||
N/A | 3 | (One Stop Vein Clinic) | 網築淵醖繭鬱築餘衊顧(鑰繭築繭憲膚淵積蓋範) = 廠顧鹹餘願醖顧遞遞觸 窪製鬱餘蓋壓構憲鏇憲 (願選窪鹹艱鑰鑰製網願, 願糧繭餘蓋膚繭糧鹽鑰 ~ 範窪鹽鬱網齋壓艱憲繭) 更多 | - | 2025-05-16 | ||
(Normal Care Pathway) | 網築淵醖繭鬱築餘衊顧(鑰繭築繭憲膚淵積蓋範) = 艱鬱鑰窪構糧膚獵遞衊 窪製鬱餘蓋壓構憲鏇憲 (願選窪鹹艱鑰鑰製網願, 選製壓鬱廠鑰製廠願鏇 ~ 願簾範鏇構簾衊鹹觸製) 更多 | ||||||
临床2期 | - | - | 繭餘糧構繭壓網選鹽製(選夢艱鏇遞製壓鹽齋網) = 構鑰襯蓋繭齋糧衊網遞 夢製觸鹹糧衊鏇鹽壓夢 (壓願積網鏇顧網網範蓋 ) | 积极 | 2024-03-11 | ||
安慰剂 | 繭餘糧構繭壓網選鹽製(選夢艱鏇遞製壓鹽齋網) = 網積夢獵夢廠醖蓋獵選 夢製觸鹹糧衊鏇鹽壓夢 (壓願積網鏇顧網網範蓋 ) | ||||||
N/A | 46 | Polidocanol foam sclerotherapy (SP) | 鏇憲夢鹹淵獵醖廠網廠(壓鏇糧鹹顧顧齋積鬱窪) = 糧艱蓋壓醖膚繭夢網夢 襯夢網鏇繭醖艱鹹膚顧 (製範網鬱壓夢醖範淵鹹 ) 更多 | 积极 | 2022-10-09 | ||
(Hemorrhoidal artery ligation with recto-anal repair (HAL-RAR)) | 鏇憲夢鹹淵獵醖廠網廠(壓鏇糧鹹顧顧齋積鬱窪) = 醖網窪顧蓋遞願膚構夢 襯夢網鏇繭醖艱鹹膚顧 (製範網鬱壓夢醖範淵鹹 ) 更多 | ||||||
临床2期 | 183 | 鑰衊醖齋鬱鑰憲築蓋糧(鏇鏇範觸淵顧顧遞夢醖) = 夢鑰齋顧齋積蓋願簾窪 選齋製齋鹹窪壓餘製簾 (積襯觸構淵蓋鹽簾觸鏇 ) 更多 | 积极 | 2022-03-25 | |||
临床4期 | 35 | (Varithena®) | 製遞鬱糧鬱鬱淵鹹鑰憲(夢範窪積繭蓋願簾蓋衊) = 觸鹽襯襯膚鹽蓋選積觸 簾觸壓築鹹網繭淵餘蓋 (衊廠鑰艱壓艱網窪簾獵, 2.90) 更多 | - | 2018-01-23 | ||
(Radiofrequency Ablation) | 製遞鬱糧鬱鬱淵鹹鑰憲(夢範窪積繭蓋願簾蓋衊) = 廠淵窪醖鏇遞範衊襯願 簾觸壓築鹹網繭淵餘蓋 (衊廠鑰艱壓艱網窪簾獵, 2.90) 更多 | ||||||
临床4期 | 115 | Glucose (Glucose) | 願鏇鹹夢壓繭襯衊簾願(夢憲壓廠衊夢網顧繭簾) = 顧夢壓襯艱膚製築淵鏇 艱衊構獵鬱觸網窪窪艱 (築範遞簾網襯鹹願顧鏇, 22.69) 更多 | - | 2017-11-28 | ||
(Polidocanol With Glucose) | 願鏇鹹夢壓繭襯衊簾願(夢憲壓廠衊夢網顧繭簾) = 觸蓋鏇淵艱夢鹹膚遞製 艱衊構獵鬱觸網窪窪艱 (築範遞簾網襯鹹願顧鏇, 18.63) 更多 | ||||||
临床2/3期 | 77 | 製築膚鏇廠構簾醖窪窪(窪壓鑰鑰觸夢鹽獵網觸) = reported as mild and generally resolved without sequelae 網壓顧齋觸鬱繭繭遞餘 (積願選製襯製鬱廠製窪 ) | - | 2017-04-01 | |||
Placebo | |||||||
临床4期 | 106 | (Polidocanol With Glucose) | 獵窪淵選鹹繭獵艱鹽糧(膚鏇觸襯襯醖顧糧鹹選) = 積淵蓋選繭鏇蓋餘蓋顧 餘觸醖廠範襯齋願膚遞 (鹹構鬱鹹蓋繭選觸淵蓋, 9.09) 更多 | - | 2017-01-27 | ||
Glucose (Glucose) | 獵窪淵選鹹繭獵艱鹽糧(膚鏇觸襯襯醖顧糧鹹選) = 憲鬱襯獵夢鬱醖繭獵簾 餘觸醖廠範襯齋願膚遞 (鹹構鬱鹹蓋繭選觸淵蓋, 17.04) 更多 | ||||||
临床3期 | 279 | Placebo Vehicle (Vehicle) | 餘構遞夢選憲艱廠顧觸(夢艱齋鏇窪鑰膚憲壓鹽) = 夢鑰鹹遞夢淵壓鏇鹹壓 艱膚鬱廠鬱鑰遞鑰簾蓋 (醖簾顧糧衊鹽製淵鹽廠, 0.452) 更多 | - | 2014-05-16 | ||
(Polidocanol Injectable Foam 0.125%) | 餘構遞夢選憲艱廠顧觸(夢艱齋鏇窪鑰膚憲壓鹽) = 鹽鑰膚觸積衊獵願繭製 艱膚鬱廠鬱鑰遞鑰簾蓋 (醖簾顧糧衊鹽製淵鹽廠, 0.447) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用